Pediatric Pneumococcal Serotypes in 4 European Countries
After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children <15 years of age were compared between 1999–2002 (...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2010-09-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/16/9/10-0102_article |
| _version_ | 1818180302759002112 |
|---|---|
| author | Germaine Hanquet Esther Kissling Asuncion Fenoll Robert C. George Agnes Lepoutre Tinne Lernout David Tarragó Emmanuelle Varon Jan Verhaegen |
| author_facet | Germaine Hanquet Esther Kissling Asuncion Fenoll Robert C. George Agnes Lepoutre Tinne Lernout David Tarragó Emmanuelle Varon Jan Verhaegen |
| author_sort | Germaine Hanquet |
| collection | DOAJ |
| description | After heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children <15 years of age were compared between 1999–2002 (prevaccine) and 2005–2006 (postmarketing). Vaccine coverage increased to ≈32%–48% in France, Spain, and Belgium but remained <1% in England and Wales. Serotype 1 incidence rose in all age groups and countries (incidence rate ratio [IRR] 1.3–4.2; p<0.004), independently of PCV7 use, but incidence of serotypes 7F and 19A increased most in France, Spain, and Belgium (IRR 1.9–16.9 in children <5 years; p<0.001), where PCV7 coverage was greater. Vaccine-induced replacement of PCV7 serotypes possibly contributed to NVT increases, as did secular trends. New vaccines targeting these serotypes are available, but serotype dynamics needs further exploration that accounts for underreporting and prevaccine trends. |
| first_indexed | 2024-12-11T21:17:37Z |
| format | Article |
| id | doaj.art-1c2588105caf4b39b5e83394aeee39d5 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-11T21:17:37Z |
| publishDate | 2010-09-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-1c2588105caf4b39b5e83394aeee39d52022-12-22T00:50:33ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592010-09-011691428143910.3201/eid1609.100102Pediatric Pneumococcal Serotypes in 4 European CountriesGermaine HanquetEsther KisslingAsuncion FenollRobert C. GeorgeAgnes LepoutreTinne LernoutDavid TarragóEmmanuelle VaronJan VerhaegenAfter heptavalent pneumococcal conjugate vaccine (PCV7) was marketed in France, Spain, Belgium, and England and Wales (United Kingdom), invasive disease from non-PCV7 serotypes (NVT) increased. Adjusted serotype-specific incidences among children <15 years of age were compared between 1999–2002 (prevaccine) and 2005–2006 (postmarketing). Vaccine coverage increased to ≈32%–48% in France, Spain, and Belgium but remained <1% in England and Wales. Serotype 1 incidence rose in all age groups and countries (incidence rate ratio [IRR] 1.3–4.2; p<0.004), independently of PCV7 use, but incidence of serotypes 7F and 19A increased most in France, Spain, and Belgium (IRR 1.9–16.9 in children <5 years; p<0.001), where PCV7 coverage was greater. Vaccine-induced replacement of PCV7 serotypes possibly contributed to NVT increases, as did secular trends. New vaccines targeting these serotypes are available, but serotype dynamics needs further exploration that accounts for underreporting and prevaccine trends.https://wwwnc.cdc.gov/eid/article/16/9/10-0102_articleInvasive pneumococcal diseasepneumococcal conjugate vaccinesserotypebacteriaFranceSpain |
| spellingShingle | Germaine Hanquet Esther Kissling Asuncion Fenoll Robert C. George Agnes Lepoutre Tinne Lernout David Tarragó Emmanuelle Varon Jan Verhaegen Pediatric Pneumococcal Serotypes in 4 European Countries Emerging Infectious Diseases Invasive pneumococcal disease pneumococcal conjugate vaccines serotype bacteria France Spain |
| title | Pediatric Pneumococcal Serotypes in 4 European Countries |
| title_full | Pediatric Pneumococcal Serotypes in 4 European Countries |
| title_fullStr | Pediatric Pneumococcal Serotypes in 4 European Countries |
| title_full_unstemmed | Pediatric Pneumococcal Serotypes in 4 European Countries |
| title_short | Pediatric Pneumococcal Serotypes in 4 European Countries |
| title_sort | pediatric pneumococcal serotypes in 4 european countries |
| topic | Invasive pneumococcal disease pneumococcal conjugate vaccines serotype bacteria France Spain |
| url | https://wwwnc.cdc.gov/eid/article/16/9/10-0102_article |
| work_keys_str_mv | AT germainehanquet pediatricpneumococcalserotypesin4europeancountries AT estherkissling pediatricpneumococcalserotypesin4europeancountries AT asuncionfenoll pediatricpneumococcalserotypesin4europeancountries AT robertcgeorge pediatricpneumococcalserotypesin4europeancountries AT agneslepoutre pediatricpneumococcalserotypesin4europeancountries AT tinnelernout pediatricpneumococcalserotypesin4europeancountries AT davidtarrago pediatricpneumococcalserotypesin4europeancountries AT emmanuellevaron pediatricpneumococcalserotypesin4europeancountries AT janverhaegen pediatricpneumococcalserotypesin4europeancountries |